title: Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
abstract: OBJECTIVE
  The industry perspective on drug costs should be framed by the need for decision-makers to use actual and relevant costs, and to inform real-world decisions regarding medication selection and use. The objective of this report is to provide guidance and recommendations on how manufacturers should approach the use of drug costs.
  
  
  METHODS
  The Task Force was appointed with the advice and consent of the ISPOR Board of Directors. Members were experienced developers or users of drug cost information working in academia and industry, and came from several countries. Following the core assumptions developed and outlined by the Task Force, a draft report was prepared. Comments were solicited on the outline and several draft reports both from a core group of external reviewers and more broadly from the ISPOR membership of ISPOR via the ISPOR Web site.
  
  
  RESULTS
  The industry should always strive for: 1) a focus on drug value and not just cost; 2) credibility-that is correct and consistent costs; 3) transparency-by disclosing the prices and costs, and ensuring that they reflect the actual cost of the drug whenever possible; and 4) providing actionable results that help customers comprehend the value offered by a drug therapy and to use products more efficiently and effectively.
  
  
  CONCLUSIONS
  Understanding and accounting for all costs and consequences of the use of a medical treatment is in the best interests of all parties involved in the prescribing, consuming, reimbursement, selling, and manufacturing of bio/pharmaceuticals. Transparency, consistency, and clear communication of costs and value are essential for appropriate decision-making and should be important goals for all parties.
authors.affiliation: MME LLC, Montclair, NJ 07042, USA. jmycka@m2econ.com
authors.forename: Jack M
authors.initials: JM
authors.lastname: Mycka
authors.forename: Renato
authors.initials: R
authors.lastname: Dellamano
authors.forename: Eugene Mick
authors.initials: EM
authors.lastname: Kolassa
authors.forename: Michael
authors.initials: M
authors.lastname: Wonder
authors.forename: Sabyasachi
authors.initials: S
authors.lastname: Ghosh
authors.forename: Joel W
authors.initials: JW
authors.lastname: Hay
authors.forename: Jim
authors.initials: J
authors.lastname: Smeeding
mesh_terms: D003362:Cost-Benefit Analysis / Q000379:methods*; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics* / Q000592:standards; D017850:Economics, Pharmaceutical; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000592:standards; D011306:Prescription Fees / Q000592:standards*